<DOC>
	<DOCNO>NCT00379119</DOCNO>
	<brief_summary>RATIONALE : Studying change thymus function patient undergo androgen blockade therapy prostate cancer may help doctor learn well patient respond treatment , may help plan cancer treatment , may help study cancer future . PURPOSE : This clinical trial study effect androgen blockade therapy thymus function old patient undergone radical prostatectomy localized prostate cancer .</brief_summary>
	<brief_title>Effect Androgen Blockade Therapy Thymus Function Older Patients Who Have Undergone Radical Prostatectomy Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine inhibition sex steroid action associate increase thymic size old patient undergone radical prostatectomy localize adenocarcinoma prostate . - Determine inhibition sex steroid action associate increase absolute number percentage circulate `` naive '' phenotype T cell , and/or increase frequency T-cell receptor excision circle peripheral blood cell . OUTLINE : This nonrandomized , single-blind , cohort study . Patients stratify accord hormonal therapy surgery ( yes v ) . Patients undergo CT scan thymus . Blood sample analyze flow cytometry determine phenotype T cell . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Underwent prior radical prostatectomy local definitive therapy prostate cancer Meets criteria 1 follow stratum : Has receive ≥ 9 month androgen blockade therapy ( either singleagent luteinizing hormonereleasing hormone combine androgen blockade ) serologic progression surgery Serologic progression define rise prostatespecific antigen , rise serially two determination ( baseline ) ≥ 1 week apart , objective evidence metastatic disease Prior radiotherapy serologic progression allow Did receive form androgen blockade therapy within past 9 month No metastatic disease abdominal/pelvic CT scan wholebody scan PATIENT CHARACTERISTICS : Able tolerate CT scan supine position No prior medical condition know effect thymus , include myasthenia gravis , lymphoma , hyperthyroidism , cachexia No autoimmune disorder No acute illness , include active infection require antibiotic PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic chemotherapy No prior immunological therapy No prior singleagent antiandrogen ( e.g. , highdose bicalutamide ) No prior concurrent 5alpha reductase inhibitor ( e.g. , finasteride ) , PCSPES , estrogencontaining nutraceuticals No concurrent systemic steroid therapy ( topical steroid allow )</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>